Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.08M | 891.40K | 891.40K | 612.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.08M | 891.40K | 891.40K | 612.70K |
| Cost of Revenue | -- | 650.70K | 506.10K | 506.10K | 360.30K |
| Gross Profit | -- | 424.40K | 385.20K | 385.20K | 252.30K |
| SG&A Expenses | -- | 617.10K | 492.10K | 492.10K | 467.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 1.29M | 1.14M | 1.14M | 1.09M |
| Operating Income | -- | -216.60K | -247.70K | -247.70K | -477.50K |
| Income Before Tax | -- | -263.40K | -291.90K | -291.90K | -523.80K |
| Income Tax Expenses | -- | 1.20K | -- | -- | -- |
| Earnings from Continuing Operations | -- | -0.26 | -0.29 | -0.29 | -0.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -264.60K | -291.90K | -291.90K | -523.80K |
| EBIT | -- | -216.60K | -247.70K | -247.70K | -477.50K |
| EBITDA | -- | -162.20K | -207.40K | -207.40K | -393.30K |
| EPS Basic | -- | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -- | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -- | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -- | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | -- | 216.00M | 216.00M | 216.00M | 216.00M |
| Average Diluted Shares Outstanding | -- | 216.00M | 216.00M | 216.00M | 216.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |